| DC Field | Value | Language |
|---|
| dc.contributor.author | Koklin, I. S. | - |
| dc.contributor.author | Lebedev, P. R. | - |
| dc.contributor.author | Kochkarov, A. A. | - |
| dc.contributor.author | Gudyrev, O. S. | - |
| dc.contributor.author | Gureev, V. V. | - |
| dc.contributor.author | Dolzhikov, A. A. | - |
| dc.contributor.author | Taran, E. I. | - |
| dc.contributor.author | Korokin, M. V. | - |
| dc.date.accessioned | 2025-11-17T09:18:44Z | - |
| dc.date.available | 2025-11-17T09:18:44Z | - |
| dc.date.issued | 2025 | - |
| dc.identifier.citation | Regulation of 11β-hydroxysteroid dehydrogenase isoforms – novel drug targets for osteoporosis therapy / I.S. Koklin, P.R. Lebedev, A.A. Kochkarov [et al.] // Research Results in Pharmacology. - 2025. - Vol.11, №3.-P. 109-114. - Doi: 10.18413/rrpharmacology.11.807. - Refer.: p. 113-114. | ru |
| dc.identifier.uri | http://dspace.bsuedu.ru/handle/123456789/65888 | - |
| dc.description.abstract | The development of azole-based heterocyclic 11β-HSD1 inhibitors is expected to yield promising drug candidates for pharmacologically correcting impaired bone remodeling and repair | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | osteoporosis | ru |
| dc.subject | 11β-hydroxysteroid dehydrogenase | ru |
| dc.subject | regulation | ru |
| dc.subject | 11β-HSD inhibitors | ru |
| dc.subject | drug targets | ru |
| dc.title | Regulation of 11β-hydroxysteroid dehydrogenase isoforms – novel drug targets for osteoporosis therapy | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 11, № 3
|
